Boston Scientific Corporation
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.97B | $414.0M | $865.0M | $928.0M | $1.93B | $1.73B | $217.0M | $146.0M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | $2.94B | $2.81B | $2.48B | $1.87B | $1.61B | $1.35B | $1.58B | $1.17B |
| Total Current Assets | $8.79B | $6.92B | $6.51B | $5.76B | $6.32B | $6.69B | $4.70B | $4.00B |
| Property, Plant & Equipment | $4.04B | $3.29B | $2.86B | $2.45B | $2.25B | $2.08B | $2.08B | $1.78B |
| Goodwill | $18.28B | $17.09B | $14.39B | $12.92B | $11.99B | $9.95B | $10.18B | $7.91B |
| Intangible Assets (Excl. Goodwill) | $7.02B | $6.68B | $6.00B | $5.90B | $6.12B | $5.92B | $7.89B | $6.37B |
| Total Assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B | $30.78B | $30.57B | $21.00B |
| Liabilities | ||||||||
| Accounts Payable | $1.14B | $960.0M | $942.0M | $862.0M | $794.0M | $513.0M | $542.0M | $349.0M |
| Total Current Liabilities | $5.44B | $6.40B | $4.93B | $3.80B | $4.27B | $3.68B | $4.87B | $5.26B |
| Long-Term Debt | $11.14B | $8.97B | $8.57B | $8.92B | $8.80B | $9.13B | $8.59B | $4.80B |
| Total Liabilities | $19.44B | $17.63B | $15.85B | $14.90B | $15.61B | $15.45B | $16.69B | $12.27B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $5.57B | $2.67B | $819.0M | $-750.0M | $-1.39B | $-2.38B | $-2.25B | $-6.95B |
| Total Stockholders' Equity | $24.23B | $21.77B | $19.28B | $17.57B | $16.62B | $15.33B | $13.88B | $8.73B |